Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)

Inclusion Criteria: * Histologically proven non-small cell lung cancer (squamous cell carcinoma, adenocarcinoma, large cell carcinoma and etc) * Tumor EGFR mutation * Presence of measurable disease by RECIST * stage IIIA or IIIB, non-resectable * ECOG performance status 0-2 * No prior chemotherapy, radiation therapy to chest, immunotherapy, or biologic therapy * Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital. Exclusion Criteria: * Carcinoid tumor, small cell carcinoma of lung * Patients with any distant metastasis * History of another malignancy except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix * Any other morbidity or situation with contraindication for radiotherapy (e.g. active infection, myocardial infarction preceding 6 months, symptomatic heart disease including unstable angina, congestive heart failure or uncontrolled arrhythmias, immunosuppressive treatment) * Pregnant or lactating women, women who has not taken test of pregnancy (within 7 days before the first administration) and pregnant women * Women and men of childbearing potential who have no willing of employing adequate contraception * Tumor EGFR wild